Argos Therapeutics, Inc. (ARGS)

Trade ARGS now with
9/26/2017 4:34:38 PM Argos Therapeutics Appoints Richard Morrison To Board Of Directors
9/12/2017 8:15:42 AM Argos Therapeutics Reports On Update On Interim Analysis Of Phase 3 ADAPT Trial Presented At ESMO 2017 Congress
8/21/2017 8:32:36 AM Argos Therapeutics Announces Interim Analysis Of Phase 3 ADAPT Trial To Be Presented At ESMO 2017 Congress
6/22/2017 8:02:49 AM Argos Therapeutics Announces Closing Of $6.0 Mln Secured Convertible Note Financing
5/10/2017 8:13:15 AM Argos Says FDA Agreed With Plan To Continue ADAPT Trial In Accordance With Current Protocol To 290 Events
2/22/2017 8:11:01 AM Argos Therapeutics Trading Expected To Resume At 8:30 AM ET
2/22/2017 8:09:39 AM Argos :IDMC Recommends Discontinuation Of ADAPT Phase 3 Trial Of Rocapuldencel-T In Metastatic Renal Cell Carcinoma
2/22/2017 8:02:42 AM Argos Therapeutics Trading Halted; Pending News
12/14/2016 8:06:37 AM Argos Therapeutics Enters Strategic Research Agreement With Personalis
11/18/2016 8:03:20 AM Cellthera Demonstrates Functional Activity Of AGS-003-like Therapy In Kidney Cancer Murine Model
11/14/2016 6:37:18 AM Argos Therapeutics Q3 Net Loss $12.2 Mln Or $0.32/shr Vs Loss Of $20.1 Mln Or $0.97/shr Last Year
11/3/2016 9:01:04 AM Argos Announces Publication Of A Case Report On Long-term Survival Of Kidney Cancer Patients Treated With AGS-003
7/28/2016 9:23:57 AM Argos Therapeutics Announces Pricing Of $50 Mln Public Offering Of Common Stock And Warrants
7/14/2016 8:33:39 AM Argos Announces First Patient Dosed In Stage 2 Of Adult Eradication Trial Of AGS-004 In The Treatment Of HIV
7/11/2016 8:03:35 AM Argos Therapeutics Announces Richard Katz As CFO